Evidence map›Paper›PMID 39340046›Full record

ArticleVaccines2024

COVID-19 Vaccine: A Potential Risk Factor for Accelerating the Onset of Bullous Pemphigoid.

Anna Pira, Feliciana Mariotti, Francesco Moro, Biagio Didona, Giovanni Luca Scaglione, Annarita Panebianco, Damiano Abeni, Giovanni Di Zenzo

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anna PiraMolecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.ORCID 0000-0001-7172-619X
Feliciana MariottiMolecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.ORCID 0000-0002-7004-5031
Francesco MoroMolecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.
Biagio DidonaRare Diseases Unit, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.
Giovanni Luca ScaglioneBioinformatic Unit, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.ORCID 0000-0001-5622-7843
Annarita PanebiancoMedical Direction, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.
Damiano AbeniClinical Epidemiology Unit, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.
Giovanni Di ZenzoMolecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.ORCID 0000-0001-6106-599X

Funding

Ministero della Salute 12367807
6 · The paper itself

Abstract

Bullous pemphigoid (BP) is the most common autoimmune bullous disease, whose main autoantigens are hemidesmosomal components BP180 and BP230. Although recent studies found no association between COVID-19 vaccines and BP, since mass vaccinations started, more than 90 vaccine-associated BP cases have been reported. To find an agreement among real-life clinical observations and recent epidemiologic data, we further investigated this topic. A total of 64 patients with BP onset in 2021 were demographically, clinically, and serologically characterized: 14 (21.9%) vaccine-associated patients (VA) developed BP within 5 weeks from the first/second vaccine dose. VA and vaccine-non-associated (VNA) patients had similar demographics and clinical and immunological characteristics. Noteworthy, the monthly distribution of BP onset during mass vaccinations paralleled vaccine administration to the elderly in the same catchment area. Additionally, in 2021, BP onsets in April-May and June-July significantly increased (

Indexed as

autoimmune bullous diseasebullous pemphigoidCOVID-19pandemicSARS-CoV-2vaccine

Identifiers

PMID39340046
PMCPMC11436231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.